# Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases

> **NCT04037241** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Sorrento Therapeutics, Inc.**

## Conditions studied

- Malignant Tumor of Pancreas Metastatic to Liver

## Interventions

- **BIOLOGICAL:** Anti-CEA CAR-T cells
- **DRUG:** gemcitabine/nab paclitaxel
- **DRUG:** NLIR+FU/FA
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT04037241
- **Lead sponsor:** Sorrento Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-11-01
- **Primary completion:** 2022-01-01
- **Final completion:** 2022-01-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor terminated
- **Last updated:** 2022-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04037241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04037241, "Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04037241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*